Takeda Pharmaceutical Company Limited
A maker of medicines for the gut, cancer, and rare diseases, Takeda is one of the world's largest pharmaceutical companies. Its drugs include Entyvio for Crohn's disease and ulcerative colitis, and it sells treatments across dozens of countries. Founded in Osaka in 1781 by Chobei Takeda, it began as a small shop selling herbal remedies in the city's medicine district before moving into Western drugs and manufacturing. The name simply comes from its founding family, who guided the firm for generations before it grew into a global player.
Sponsored American Depositary Receipt (ADR)
Granted 212.5K · Sold 19.7K
Granted 105.4K
Granted 244.3K
Granted 72.1K
Granted 65.0K
Granted 60.0K
Granted 27.7K
Granted 35.0K
Granted 7.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Plump Andrew StewartPresident, R&D, Director · 2 transactions | — | 1.90M | 212.5K | — | 19.7K |
| Kim Julie So-YoungCEO - Elect · 1 transaction | — | 430.1K | 105.4K | — | — |
| Weber Christophe PierrePresident and CEO, Director · 2 transactions | — | 418.8K | 244.3K | — | — |
| Platford Giles RichardPresident, IBU · 1 transaction | — | 297.4K | 72.1K | — | — |
| Bitetti Teresa MariePresident, OBU · 1 transaction | — | 258.1K | 65.0K | — | — |
| Duprey Lauren RusckowskiChief Transformation Officer · 1 transaction | — | 228.5K | 60.0K | — | — |
| Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev. · 1 transaction | — | 172.3K | 27.7K | — | — |
| Ricci GabrieleChief Data & Tech. Officer · 1 transaction | — | 159.1K | 35.0K | — | — |
| Furuta MilanoChief Financial Officer, Director · 1 transaction | — | 57.9K | 7.8K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -19.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.